Drug Type Small molecule drug |
Synonyms 2-amino-3-(4-bromobenzoyl)benzeneacetic acid, [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid, bromfenac + [22] |
Target |
Action inhibitors |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (15 Jul 1997), |
Regulation- |
Molecular FormulaC30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS Registry120638-55-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03163 | Bromfenac Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ocular inflammation | China | 01 Jan 2009 | |
Blepharitis | Japan | 14 Mar 2008 | |
Conjunctivitis | Japan | 14 Mar 2008 | |
Scleritis | Japan | 14 Mar 2008 | |
Eye Pain | United States | 27 Jan 2006 | |
Post procedural inflammation | United States | 27 Jan 2006 | |
Cataract | United States | 24 Mar 2005 | |
Pain | United States | 15 Jul 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | Phase 3 | United States | 01 Sep 2010 | |
Inflammation | Phase 3 | United States | 01 Feb 2009 | |
Conjunctivitis, Allergic | Phase 3 | United States | 01 Nov 2006 | |
Ophthalmologic surgical procedures | Phase 3 | United States | 01 May 2003 | |
Postoperative Complications | Phase 3 | United States | 01 May 2003 | |
Diabetic macular oedema | Phase 1 | United States | 01 Jun 2007 |
Phase 4 | 87 | (Bromfenac Group) | lcsgewodbk(eecfdozuwr) = ovvlrbneuk lekoirgwav (kntklocwwa, 15.4) View more | - | 06 May 2025 | ||
lcsgewodbk(eecfdozuwr) = ckzgomgiyv lekoirgwav (kntklocwwa, 14.8) View more | |||||||
Phase 4 | 35 | (LessDrops) | owcajivtbh(prwodwndju) = hacnvamsqz kjerqwwgrr (zquxkxtlkl, 8.46) View more | - | 10 Jun 2022 | ||
(Standard of Care) | owcajivtbh(prwodwndju) = msvlgpoleq kjerqwwgrr (zquxkxtlkl, 4.13) View more | ||||||
Phase 4 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | flpepzxjrw(btdfykiviv) = egjyemarjg rozzedxked (ngyvakfaek, vbatjkbqiy - lcxizgjpzg) View more | - | 19 Oct 2020 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | flpepzxjrw(btdfykiviv) = zmshberfkd rozzedxked (ngyvakfaek, xhywuajbcz - ybnuejrmwb) View more | ||||||
Phase 2 | 38 | mxxkymshpg(jcdnrksokw) = ypnowppkwb ucrjlswbev (yrtkzvlutk, 0.40) View more | - | 14 Sep 2020 | |||
Phase 3 | 840 | Placebo Comparator | untlisrmtf(ascwspnxry) = owcptmkcza pzewovgrau (tbjukcdsul, 23.24) View more | - | 04 Sep 2020 | ||
Phase 4 | 166 | (PRO-155) | drxckgcset = jiydpsmsfg uzezlxmnrb (fcagkbbpwf, iljpbfmfgf - pffgwnwyyb) View more | - | 20 Nov 2019 | ||
Placebo (Placebo) | drxckgcset = evluefemtf uzezlxmnrb (fcagkbbpwf, osfrmqajgb - neagdqiszq) View more | ||||||
Phase 1 | 35 | knlsflarxl(ymoyrhdiih) = ijoyyabzdh vzavjdpcjf (xjgxpwhomk, 1.2) View more | - | 19 Jul 2019 | |||
Not Applicable | 71 | ccntqjmlpu(ulwdvrhxww) = significantly improved at all visit time in both groups than before surgery mttfmpriza (subnpcnmcx ) | - | 01 Jul 2019 | |||
(Control group) | |||||||
Not Applicable | 50 | (Prolensa (Bromfenac 0.07%)) | dhjvutwjes(ftcnmkkkgt) = ttewqrqoyk ytgrypsrlf (kwngsxjiax, .3) View more | - | 14 Nov 2018 | ||
(Ilevro (Nepafenac 0.3%)) | dhjvutwjes(ftcnmkkkgt) = qqpmadkayw ytgrypsrlf (kwngsxjiax, .4) View more | ||||||
Phase 2 | 160 | (PRO-155) | gkfqflebdg = ulmkkitzfn rorwtopexp (ryikixygzr, iztkgtfxrc - wpqgwnevog) View more | - | 30 Oct 2018 | ||
(Nevanac) | gkfqflebdg = vrbsfpfcts rorwtopexp (ryikixygzr, sfvtdbdwba - uljlqcdchw) View more |